ActivistsInvestorsTrumpPoliticiansSerenityCitriniBurrySemianalysisSwingTradeArbitrageSearch

$DYN:NASDAQ · DYNE THERAPEUTICS INC

Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States.

More about this company

Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. The company is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.

Sector: health

Conviction from: NASDAQCitrini

52-week range: 14.0027.30

2 tracked filer(s) hold this · 1 opened, 1 added, 0 trimmed in 30-SEP-2026

Aggregate 13FScore 42 — mean of 2 scored holder(s) · buyers (new/add) avg 42. Higher = the smart money in this name has the better track record.

Filer13FScoreThis quarterSharesValue% of their book
George Soros / Soros Fund Mgmt33New buy20,000$322,2000.0%
Louis Bacon / Moore52Added +28%390,737$6,294,7730.1%

Beyond 13F — activists, insiders, politicians & research

Citrini Research coverage report library →

ReportDateStance
#97 — Rough Seas Make Strong Sailors: Navigating the Healthcare Policy Tsunami2025-05-28LONG

Every tracked holder of this name, sorted new → added → flat → trimmed. Shares = reported 13F share count; Value as reported (a few managers file values in $thousands). Generated 2026-11-17.